These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 25884534)

  • 1. Pharmacokinetics of continuous-infusion meropenem for the treatment of Serratia marcescens ventriculitis in a pediatric patient.
    Cies JJ; Moore WS; Calaman S; Brown M; Narayan P; Parker J; Chopra A
    Pharmacotherapy; 2015 Apr; 35(4):e32-6. PubMed ID: 25884534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Serratia marcescens meningitis with prolonged infusion of meropenem.
    Nicasio AM; Quintiliani R; DeRyke CA; Kuti JL; Nicolau DP
    Ann Pharmacother; 2007 Jun; 41(6):1077-81. PubMed ID: 17472997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of continuous-infusion meropenem in a pediatric patient receiving extracorporeal life support.
    Cies JJ; Moore WS; Dickerman MJ; Small C; Carella D; Chopra A; Parker J
    Pharmacotherapy; 2014 Oct; 34(10):e175-9. PubMed ID: 25146254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid penetration of meropenem in neurocritical care patients with proven or suspected ventriculitis: a prospective observational study.
    Blassmann U; Roehr AC; Frey OR; Vetter-Kerkhoff C; Thon N; Hope W; Briegel J; Huge V
    Crit Care; 2016 Oct; 20(1):343. PubMed ID: 27776537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A dosing nomograph for cerebrospinal fluid penetration of meropenem applied by continuous infusion in patients with nosocomial ventriculitis.
    König C; Grensemann J; Czorlich P; Schlemm E; Kluge S; Wicha SG
    Clin Microbiol Infect; 2022 Jul; 28(7):1022.e9-1022.e16. PubMed ID: 35182756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial infections.
    Pai MP; Cojutti P; Pea F
    Clin Pharmacokinet; 2015 Sep; 54(9):933-41. PubMed ID: 25850987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraventricular daptomycin and intravenous linezolid for the treatment of external ventricular-drain-associated ventriculitis due to vancomycin-resistant Enterococcus faecium.
    Mueller SW; Kiser TH; Anderson TA; Neumann RT
    Ann Pharmacother; 2012 Dec; 46(12):e35. PubMed ID: 23232018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrathecal penetration of meropenem and vancomycin administered by continuous infusion in patients suffering from ventriculitis-a retrospective analysis.
    Mader MM; Czorlich P; König C; Fuhrmann V; Kluge S; Westphal M; Grensemann J
    Acta Neurochir (Wien); 2018 Nov; 160(11):2099-2105. PubMed ID: 30242495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modelling and Monte Carlo simulation.
    Lodise TP; Nau R; Kinzig M; Drusano GL; Jones RN; Sörgel F
    J Antimicrob Chemother; 2007 Nov; 60(5):1038-44. PubMed ID: 17785282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics of meropenem in pancreatic juice and site-specific pharmacodynamic target attainment against Gram-negative bacteria: dosing considerations.
    Kondo N; Ikawa K; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Ohge H; Morikawa N; Sueda T
    Pancreatology; 2014; 14(2):95-9. PubMed ID: 24650961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multidrug-resistant Klebsiella oxytoca ventriculitis, successfully treated with intraventricular tigecycline: A case report.
    Soto-Hernández JL; Soto-Ramírez A; Pérez-Neri I; Angeles-Morales V; Cárdenas G; Barradas VA
    Clin Neurol Neurosurg; 2020 Jan; 188():105592. PubMed ID: 31760254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibacterial therapeutic drug monitoring in cerebrospinal fluid: difficulty in achieving adequate drug concentrations.
    Lonsdale DO; Udy AA; Roberts JA; Lipman J
    J Neurosurg; 2013 Feb; 118(2):297-301. PubMed ID: 23121433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of continuous-infusion meropenem in pediatric hematopoietic stem cell transplant patients.
    Cojutti P; Maximova N; Pea F
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5535-41. PubMed ID: 26124157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae?
    Pea F; Della Siega P; Cojutti P; Sartor A; Crapis M; Scarparo C; Bassetti M
    Int J Antimicrob Agents; 2017 Feb; 49(2):255-258. PubMed ID: 28012683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meropenem pharmacokinetics, pharmacodynamics, and Monte Carlo simulation in the neonate.
    Bradley JS; Sauberan JB; Ambrose PG; Bhavnani SM; Rasmussen MR; Capparelli EV
    Pediatr Infect Dis J; 2008 Sep; 27(9):794-9. PubMed ID: 18645546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Meropenem in Neurocritical Care Patients: a Prospective Two-Center Study.
    Kumta N; Heffernan AJ; Cotta MO; Wallis SC; Livermore A; Starr T; Wong WT; Joynt GM; Lipman J; Roberts JA
    Antimicrob Agents Chemother; 2022 Aug; 66(8):e0014222. PubMed ID: 35862757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serratia marcescens prosthesis infection successfully treated with meropenem after imipenem failure.
    Lefort A; Righi S; Jauréguy F; Bégué T; Robineau M; Bouchaud O; Lortholary O
    J Infect; 2005 Aug; 51(2):E45-7. PubMed ID: 16038749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Meropenem Penetration into Cerebrospinal Fluid in Patients with Meningitis After Neurosurgery.
    Zhang Y; Zhang J; Chen Y; Yu J; Cao G; Wu X; Chen M; Wu J; Zhao X
    World Neurosurg; 2017 Feb; 98():525-531. PubMed ID: 27867128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis.
    Kuti JL; Nightingale CH; Knauft RF; Nicolau DP
    Clin Ther; 2004 Apr; 26(4):493-501. PubMed ID: 15189746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacokinetics and pharmacodynamics of meropenem in the cerebrospinal fluid of neurosurgical patients.
    Tsumura R; Ikawa K; Morikawa N; Ikeda K; Shibukawa M; Iida K; Kurisu K
    J Chemother; 2008 Oct; 20(5):615-21. PubMed ID: 19028626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.